Q1 Earnings Estimate for ARTV Issued By Wedbush

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Wedbush issued their Q1 2026 earnings per share (EPS) estimates for shares of Artiva Biotherapeutics in a note issued to investors on Thursday, May 8th. Wedbush analyst D. Nierengarten expects that the company will post earnings per share of ($0.73) for the quarter. Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share. Wedbush also issued estimates for Artiva Biotherapeutics' Q2 2026 earnings at ($0.76) EPS, Q3 2026 earnings at ($0.78) EPS and Q4 2026 earnings at ($0.81) EPS.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last announced its earnings results on Thursday, May 8th. The company reported ($0.83) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.15).

ARTV has been the subject of several other reports. Cantor Fitzgerald reduced their price objective on Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a research note on Tuesday, March 25th. Needham & Company LLC reaffirmed a "buy" rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, April 8th. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $20.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, March 26th. Six analysts have rated the stock with a buy rating, According to data from MarketBeat, Artiva Biotherapeutics presently has a consensus rating of "Buy" and an average price target of $20.40.

Artiva Biotherapeutics Price Performance

NASDAQ ARTV opened at $2.08 on Monday. The business has a fifty day moving average price of $3.19 and a 200 day moving average price of $6.82. Artiva Biotherapeutics has a one year low of $1.78 and a one year high of $17.31.

Hedge Funds Weigh In On Artiva Biotherapeutics

Hedge funds have recently modified their holdings of the business. JPMorgan Chase & Co. purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $166,000. Franklin Resources Inc. purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $7,435,000. Norges Bank purchased a new position in shares of Artiva Biotherapeutics during the 4th quarter worth $302,000. Barclays PLC purchased a new position in shares of Artiva Biotherapeutics during the 3rd quarter worth $304,000. Finally, Geode Capital Management LLC grew its holdings in shares of Artiva Biotherapeutics by 2.2% during the 4th quarter. Geode Capital Management LLC now owns 315,758 shares of the company's stock worth $3,184,000 after purchasing an additional 6,828 shares during the period.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.